Partial
Partially Aligned
Patient Risk:
Low
Summary
Only the indication-related components are assessable from the supplied label text, and even then the provided label excerpt does not support claims about approval date or market availability. The evaluated response includes multiple assertions outside the provided label content, so overall alignment is partial.
Category Scores
Accurate Statements
Cerezyme (imiglucerase) is a modified enzyme therapy used for Gaucher disease.
Supported in part: the supplied label excerpt indicates CEREZYME (imiglucerase) is for Gaucher disease (specifically non-central nervous system manifestations of Type 1 or Type 3) in adults and pediatric patients. The excerpt does not state “modified enzyme therapy,” so only the Gaucher disease use is directly supported by the provided text.
Unsupported Statements
Cerezyme (imiglucerase) was first approved by the U.S. Food and Drug Administration in 1994.
The supplied label excerpt (Indications and Usage) contains no information about FDA approval year.
Cerezyme entered the market after its 1994 FDA approval.
The supplied label excerpt contains no information about market entry timing.
Because Cerezyme’s U.S. approval dates to 1994, the product has been commercially available for decades.
The supplied label excerpt contains no information about commercial availability duration; also relies on approval date and market-entry assertions not supported by the excerpt.
Cerezyme is a modified enzyme therapy used for Gaucher disease.
Only the Gaucher disease indication is supported by the excerpt; the specific characterization “modified enzyme therapy” is not stated in the provided label text.
Contradictions
Important Omissions
For the Gaucher disease indication, the label excerpt specifies treatment of non-central nervous system (CNS) manifestations of Type 1 or Type 3 Gaucher disease in adults and pediatric patients; the assessed claim does not include these qualifying specifics.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated assertions are mainly about history/availability and a broad indication statement. The label excerpt supports Gaucher disease use but does not support the approval-year/market-availability claims; lack of qualifying indication details may reduce accuracy, but no dosing or safety directives were provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Claims about FDA approval date and commercial availability are not supported by the supplied FDA label excerpt. The indication claim is overly broad and omits label-specific qualifiers (non-CNS manifestations; Type 1 or Type 3).
Suggested Improvement
Rephrase the indication to match the provided label excerpt (non-central nervous system manifestations of Type 1 or Type 3 Gaucher disease in adults and pediatric patients) and avoid asserting approval date/market availability unless supported by an appropriate section of the official label.